Clinical Trial Update: Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 safety study of Imexon plus Docetaxel in non-small cell lung cancer, breast cancer, and prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Imexon (imexon)

Snippet

Sponsor: AmpliMed Corporation | Conditions: Non-small Cell Lung Cancer, Breast Cancer | Phase 1 | Status: COMPLETED